Last reviewed · How we verify
Placebo for levosimendan
Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand.
Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand. Used for Acute heart failure, Severe heart failure.
At a glance
| Generic name | Placebo for levosimendan |
|---|---|
| Also known as | Placebo for ODM-109 |
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | Calcium sensitizer |
| Target | Troponin C |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Levosimendan works by binding to troponin C and increasing the sensitivity of cardiac myofilaments to calcium, leading to increased cardiac contractility without increasing oxygen demand. This results in improved cardiac function without increasing the risk of arrhythmias or other adverse effects associated with traditional inotropes.
Approved indications
- Acute heart failure
- Severe heart failure
Common side effects
- Headache
- Nausea
- Dizziness
- Flushing
Key clinical trials
- Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS (PHASE3)
- Shorter Weaning From Invasive Ventilation With Levosimendan (PHASE4)
- Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage (PHASE2)
- Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock (PHASE3)
- Levosimendan In Ambulatory Heart Failure Patients (PHASE4)
- Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients (PHASE3)
- Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF (PHASE2)
- RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for levosimendan CI brief — competitive landscape report
- Placebo for levosimendan updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI